title: Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations.
authors.forename: Dirk
authors.initials: D
authors.lastname: Schürmann
authors.forename: Rob
authors.initials: R
authors.lastname: Elston
authors.forename: Fan
authors.initials: F
authors.lastname: Xu
authors.forename: Niels
authors.initials: N
authors.lastname: Kleinkauf
authors.forename: Thomas
authors.initials: T
authors.lastname: Wünsche
authors.forename: Norbert
authors.initials: N
authors.lastname: Suttorp
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D002219:Carbamates / Q000627:therapeutic use*; D024882:Drug Resistance, Viral / Q000235:genetics; D004359:Drug Therapy, Combination; D005663:Furans; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009154:Mutation; D010755:Organophosphates / Q000627:therapeutic use*; D011355:Prodrugs / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D010755:Organophosphates; D011355:Prodrugs; D013449:Sulfonamides; C095108:amprenavir; C426859:fosamprenavir